Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Legislative Overhaul 'Will Not Make EU A Global Leader' In Pharma R&D

Industry Says 'Flexible And Coherent’ Regulatory System Needed

Executive Summary

National pricing and reimbursement systems remain a key barrier to medicines access, and requiring companies to market their products in all EU countries and to notify regulators of their launch intentions is not the answer, according to EuropaBio, which represents a wide range of biotech firms operating in Europe.

You may also be interested in...



EU Actions ‘Will Weaken IP And Undermine Innovation’

In its 2022 “Special 301” submission, US pharmaceutical industry group PhRMA says that EU data protections and other incentives for innovative R&D are under threat, echoing concerns already expressed by European industry bodies.

From Innovation Mindsets To Incentives And COVID-19 Lessons: How EU Pharma Legislation Should Evolve

If the EU wants to become a more competitive space for innovation it can take a few lessons from both the US and the COVID-10 pandemic, say European pharma industry representatives. Fostering better communication between regulators and companies is just one example.

EU Extends Provisions For Ensuring Post-Brexit Flow Of Medicines

Proposals for averting medicines supply disruptions caused by Brexit in Northern Ireland and three EU markets are about to be discussed by EU legislators.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS145458

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel